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Plasma lipids and risk of developing renal dysfunction: The also been demonstrated to have adverse effects on the
Atherosclerosis Risk in Communities Study. kidney and is strongly associated with initiation [6] of
Background. Animal and in vitro data suggest that dyslipi- renal disease and accelerated loss of kidney functiondemia plays an important role in the initiation and progression
[7–9]. More recently, it has been suggested that dyslipide-of chronic renal disease, but few prospective studies have been
mia may contribute to accelerated development of renalconducted in humans.
Methods. We studied the relationship of plasma lipids to a insufficiency [10–14]. Although there is substantial ani-
rise in serum creatinine of 0.4 mg/dL or greater in 12,728 mal evidence supporting a causal relationship between
Atherosclerosis Risk in Communities (ARIC) participants with lipid levels and the development of glomerular injurybaseline serum creatinine that was less than 2.0 mg/dL in men
leading to glomerulosclerosis [15, 16], human data areand less than 1.8 mg/dL in women.
sparse [17–19]. To date, most prospective studies of lipidsResults. During a mean follow-up of 2.9 years, 191 persons
had a rise in creatinine of 0.4 mg/dL or greater, yielding an and renal disease have focused on the progression of
incidence rate of 5.1 per 1000 person years. Individuals with established renal disease rather than renal disease initia-
higher triglycerides and lower high-density lipoprotein (HDL) tion [20–23]. There is only one study, to our knowledge,and HDL-2 cholesterol at baseline were at increased risk for
that has focused on lipids predicting renal disease initia-a rise in creatinine after adjustment for race, gender, baseline
tion [10]. Therefore, little is known about the prospectiveage, diabetes, serum creatinine, systolic blood pressure, and
antihypertensive medication use (all P trends #0.02). The ad- relationship between lipids and declines in renal function
justed relative risk for the highest versus lowest quartile of among persons with normal renal function. Such infor-
triglycerides was 1.65 (95% CI, 1.1, 2.5, P 5 0.01) and for HDL mation is necessary to identify modifiable risk factorswas 0.47 (95% CI, 0.3, 0.8, P 5 0.003). These associations were
that predict development and progression of renal dis-significant in participants with normal creatinine (defined as
ease.,1.4 mg/dL for men and ,1.2 mg/dL for women), with diabe-
tes, and without diabetes. The effect of high triglycerides was We sought to determine the association of plasma
independent of plasma glucose, but was weaker and less consis- lipids with loss of renal function and the clinical onset
tent after further adjustment for fasting insulin in nondiabetics. of mild renal insufficiency. To achieve this goal, we pro-Conclusions. High triglycerides and low HDL cholesterol,
spectively assessed 12,728 participants of the Atheroscle-but not low-density lipoprotein cholesterol, predict an in-
rosis Risk in Communities (ARIC) study during threecreased risk of renal dysfunction. The treatment of these lipid
abnormalities may decrease the incidence of early renal dis- years of follow-up.
ease.
METHODS
Epidemiological studies have shown that hypertension The sample population for this study was drawn from
and dyslipidemia are both risk factors for the develop- the ARIC Study cohort, which was comprised of popula-
ment of cardiovascular disease [1–5]. Hypertension has tion-based samples from four U.S. communities: Forsyth
County, North Carolina; Jackson, Mississippi; suburban
Minneapolis, Minnesota; and Washington County, Mary-Key words: chronic renal disease, triglycerides, cholesterol, glomerular
injury, progression of renal disease. land. The complete design of ARIC has been published
previously [24]. In brief, 15,792 men and women ages 45Received for publication April 29, 1999
to 64 were recruited from 1987 through 1989 throughand in revised form September 15, 1999
Accepted for publication February 1, 2000 the use of probability sampling techniques. Follow-up
visits occurred in three-year intervals, at which time par-Ó 2000 by the International Society of Nephrology
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ticipants underwent standardized examinations in field was abstracted from questionnaires. Baseline informa-
tion on the use of antihypertensive and lipid-loweringcenter clinics. These follow-up visits included measure-
ments of demographic, lifestyle, and physiological char- medications was determined through interview and ex-
amination of pill bottles brought to the study interview.acteristics. This report is based on data from the baseline
examination and the first follow-up examination of the The presence of hypertension was defined as a systolic
blood pressure $140 mm Hg, a diastolic blood pressurecohort (1987 through 1989 and 1990 through 1993, re-
spectively). The overall ARIC cohort follow-up rate for $90 mm Hg, or the use of antihypertensive medications.
Diabetes mellitus was defined as a fasting glucose ofvisit 2 exceeded 93%.
$126 mg/dL, nonfasting glucose of $200 mg/dL, or his-
Exclusion criteria tory/treatment of diabetes. Serum glucose was assayed
by the hexokinase method. A central laboratory mea-Persons (N 5 53) with severe hypercreatinemia (Cr $
2.0 mg/dL for males, Cr $ 1.8 mg/dL for females) at sured fasting insulin with a nonspecific radioimmuno-
assay.baseline were excluded because of the high probability of
substantial renal dysfunction [25]. Participants on lipid-
Definition of outcomelowering medications at baseline (N 5 563) were also
excluded because of concerns that their baseline lipid At both the baseline and follow-up visits, serum creati-
nine was measured using a modified kinetic Jaffe methodmeasurements may not reflect their true risk profile [26].
By necessity, persons with missing data for lipids or creat- [27]. Assessment of the methodological and day-to-day
variability within ARIC participants revealed that 0.18inine at baseline (N 5 623), missing covariates (sex, race,
diabetes status, antihypertensive medication use, N 5 mg/dL (methodogical variability, SD 5 0.0494, and
within-person variability, SD 5 0.043) was the minimal48), or missing creatinine data at follow-up (N 5 1300)
were excluded. Of the 1300 participants with missing change in creatinine at which 95% confidence existed
that a true change had occurred [28]. We defined ancreatinine at follow-up, 307 had died, while 38 were miss-
ing serum measurements, and 955 (6% of visit 1 partici- incident rise in serum creatinine as a change greater than
twice this amount ($0.4 mg/dL) during the approxi-pants) did not attend ARIC visit 2. ARIC participants
who did not fast for eight hours prior to their serum mately three-year follow-up period. A change in esti-
mated creatinine clearance during follow-up was useddraw were excluded (N 5 413) from all analyses. In
addition, we limited our analysis to white and African as an additional outcome measure of change in renal
function. Creatinine clearance was estimated using theAmerican participants because of small numbers of par-
ticipants from other races (N 5 48). These exclusion Cockroft-Gault formula [29] adjusted for body size by
dividing by body surface area [30] and multiplying bycriteria left us with a population of 12,728 for our primary
analyses. 1.73. The outcome for this analysis was defined as indi-
viduals whose calculated creatinine clearance declined
Measurements by 25% or more.
Serum and ethylenediaminetetraacetic acid (EDTA)
Statistical methodsplasma from all participants were drawn at each visit.
Participants were asked to fast at least 12 hours before Plasma lipids assessed at baseline were the primary
exposures of interest. These included total cholesterol;the blood draw. Blood was drawn from the antecubital
vein while the participants were seated, and blood chem- HDL cholesterol and its subfractions, HDL-2, and HDL-3
cholesterol; LDL cholesterol; apolipoprotein A-1; apoli-istries were performed at the ARIC central chemistry
laboratory at the University of Minnesota and plasma poprotein-B; Lp(a); and triglycerides. Because of their
skewed distribution, triglycerides were log transformed.lipids at the ARIC central lipid laboratory in Houston,
Texas, USA. Plasma cholesterol, plasma triglycerides, Other variables were chosen as covariates, based on a
priori considerations, because they were thought to in-and high-density lipoprotein (HDL) cholesterol were de-
termined using enzymatic methods and low-density lipo- fluence change in serum creatinine. These included the
following clinical and demographic characteristics: gen-protein (LDL) cholesterol was calculated using the Frie-
dewald equation [27]. Apolipoproteins A-1 and B were der, race, age, diabetes mellitus, systolic blood pressure,
and baseline creatinine. Since some antihypertensivemeasured using radioimmunoassay and Lp(a) using a
double-antibody enzyme-linked immunosorbent assay medications are associated with dyslipidemia [31, 32], we
also adjusted for the type of antihypertensive medication(ELISA) technique [27] for apo(a) detection. ARIC
technicians, trained and certified in the use of a random- being taken. Antihypertensive medications were divided
into four categories: diuretics, ACE inhibitors, thiazides,zero sphygmomanometer, took three blood pressure
measurements following a standardized procedure; an and any other anti-hypertensive medication.
Length of follow-up between the ARIC baseline visitaverage of the second and third measurements was used
to estimate blood pressure. Gender and age information and the first follow-up visit (ARIC visit 2) was deter-
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Table 1. Baseline characteristics of the study population and casesmined for each participant, and the rise in serum creati-
who subsequently developed a rise in creatinine $0.4 mg/dL
nine incidence rate was calculated by quartile of lipids.
Characteristic ARIC population CasesTrends in crude incidence rates across lipid quartiles
N 12,728 191were determined using Poisson regression [33]. Poisson
Male gender 45% 51%regression was also used to determine the adjusted (for
Black race 23% 47%
the a priori chosen clinical and demographic characteris- Diabetes mellitus 10% 29%
On antihypertensive medications 23% 43%tics) relative risks and 95% confidence intervals of a rise
Hypertensive 32% 62%in serum creatinine with the lowest quartile of lipid level
Mean (SD) Mean (SD)as the comparison group. The statistical significance of
the trends in risk of a rise in serum creatinine across Age years 54 (6) 56 (6)
Creatinine mg/dL 1.09 (0.19) 1.15 (0.29)lipid quartiles was determined for the adjusted models
SBP mm Hg 121 (18) 133 (26)using the Wald test and quartile number as a continuous DBP mm Hg 74 (11) 78 (14)
variable. Total cholesterol mg/dL 215 (42) 222 (52)
Triglycerides mg/dL 128 (79) 160 (121)Analyses with lipid levels as continuous variables were
Loge triglycerides log mg/dL 4.7 (0.5) 4.9 (0.6)used to confirm the associations detected using quartile HDL cholesterol mg/dL 53 (18) 50 (15)
analyses. Relative risks in the continuous analyses are HDL-2 cholesterol mg/dL 15 (9) 13 (8)
HDL-3 cholesterol mg/dL 39 (11) 37 (11)quoted for differences that approximate the median dif-
LDL cholesterol mg/dL 135 (39) 135 (39)ference between the first and fourth quartiles (threefold Lp(a) 98 (105) 133 (134)
higher triglyceride levels and 40 mg/dL higher HDL cho- Loge Lp(a) 4.0 (1.2) 4.3 (1.2)
Apolipoprotein A-I mg/dL 133 (31) 129 (31)lesterol). Analyses with lipids as continuous variables
Apolipoprotein B mg/dL 93 (29) 97 (34)were conducted for the overall population and stratified
The study population was limited to persons without severe hypercreatinemiaby creatinine at baseline: normal creatinine (Cr # 1.3 (serum creatinine #2.0 mg/dL for males; #1.8 mg/dL for females) and not on
lipid-lowering medications.mg/dL for males, Cr # 1.1 mg/dL for females, N 5
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pres-11,323) and hypercreatinemia (1.4 # Cr # 1.9 mg/dL for sure; ARIC, Atherosclerosis Risk in Communities study.
males, 1.2 # Cr # 1.7 mg/dL for females, N 5 1818).
Analyses were also conducted stratified by race and dia-
betes and hypertension status at baseline.
cholesterol, and apolipoprotein A-1 demonstrated lowerBecause higher triglyceride levels and lower HDL cho-
incidence rates (all P # 0.05). A greater than twofoldlesterol levels are markers of the insulin-resistance syn-
difference in incidence rates across lipid quartiles oc-drome [34–36], additional analyses were performed using
curred with HDL cholesterol. The incidence of a creati-continuous lipid levels and adjusting for baseline glucose
nine rise was not associated with total cholesterol, LDLand insulin levels. Insulin levels in diabetics are consid-
cholesterol, or apolipoprotein B levels (P 5 0.31, 0.66,ered not reliable; therefore, the effect of lipid levels was
and 0.33, respectively).assessed applying insulin levels in nondiabetics and a
As shown in Table 1, individuals who later developeddummy variable for insulin levels for ARIC participants
a rise in creatinine were substantially more likely to bewith diabetes mellitus. Finally, Poisson regression mod-
black, have diabetes, and use antihypertensive medica-els were fit using a decline in creatinine clearance, ap-
tions at baseline. In addition, cases had a higher meanproximated by the Cockroft-Gault formula, 25% or more
age, baseline serum creatinine, and blood pressure. Theas the outcome. All analyses were also conducted with-
bottom row of each lipid listing in Table 2 shows theout adjustment for baseline serum creatinine and yielded
relative risk of a rise in creatinine after adjustment forsimilar results.
all of these, and other, characteristics. Quartiles of tri-
glycerides, HDL cholesterol, and HDL-2 cholesterol
RESULTS maintained strong dose response associations with an
Baseline characteristics of the ARIC participants are incident rise in creatinine (P # 0.05) after adjusting for
displayed in Table 1. The mean length of follow-up be- race, gender, age, and baseline systolic blood pressure,
tween the ARIC baseline visit and the first follow-up visit type of antihypertensive medication use, diabetes melli-
was 2.9 years. During follow-up, 1.7% of the participants tus status, and creatinine. Additionally, the relative risk
(N 5 191) experienced a creatinine rise of $0.4 mg/dL comparing the highest with the lowest quartile of HDL
(characteristics are displayed in Table 1), yielding an and HDL-2 cholesterol, and triglycerides were all sig-
overall incidence rate of 5.1 per 1000 person years of nificantly different from 1.0. The risk of a rise in creati-
follow-up. In contrast, only 0.2% had a fall of #0.4 mg/dL. nine in the highest quartile of triglycerides was 1.65 times
Higher quartiles of triglycerides and Lp(a) were asso- that for the lowest quartile (P 5 0.01). Persons in the
ciated with a higher incidence of creatinine rise (Table 2). highest quartiles of HDL cholesterol and HDL-2 choles-
terol were 0.47 and 0.57, respectively, times as likely toIn contrast, higher quartiles of HDL, HDL-2, and HDL-3
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Table 2. Incidence, adjusteda relative risks and 95% confidence intervals of a rise in creatinine $0.4 mg/dL from baseline to the 3-year
follow-up by lipid quartiles at baseline in 13,141 participants
Quartile
Lipid 1 2 3 4 P trend
Total cholesterol mg/dL
Range #186 187–212 213–239 $240
N events 45 47 45 54
Rate per 1000 patient-years 4.8 4.9 4.9 5.9 0.31
Adjusted relative riska 1.0 1.02 (0.7,1.5) 0.96 (0.7,1.5) 1.06 (0.7,1.6) 0.85
Triglycerides
Range #78 79–109 110–155 $156
N events 38 36 50 67
Rate per 1000 patient-years 4.0 3.9 5.4 7.2 0.0009
Adjusted relative riska 1.0 0.99 (0.6,1.6) 1.31 (0.9,2.0) 1.65 (1.1,2.5) 0.008
HDL cholesterol mg/dL
Range #41 42–51 52–63 $64
N events 62 48 55 26
Rate per 1000 patient-years 6.8 5.1 5.8 2.8 0.0009
Adjusted relative riska 1.0 0.73 (0.5,1.1) 0.86 (0.6,1.3) 0.47 (0.3,0.8) 0.01
HDL-2 cholesterol mg/dL
Range #9 10–13 14–19 $20
N events 72 41 49 29
Rate per 1000 patient-years 6.6 4.4 5.6 3.5 0.01
Adjusted relative riska 1.0 0.65 (0.4,1.0) 0.84 (0.6,1.2) 0.57 (0.4,0.9) 0.05
HDL-3 cholesterol mg/dL
Range #31 32–38 39–46 $47
N events 56 53 51 31
Rate per 1000 patient-years 6.3 5.2 5.5 3.5 0.02
Adjusted relative riska 1.0 0.89 (0.6,1.3) 0.99 (0.7,1.5) 0.67 (0.4,1.1) 0.17
LDL cholesterol mg/dL
Range #109 110–132 133–159 $160
N events 48 44 50 49
Rate per 1000 patient-years 5.0 4.9 5.2 5.4 0.66
Adjusted relative riska 1.0 0.97 (0.6,1.5) 0.97 (0.7,1.4) 0.90 (0.6,1.3) 0.62
Lp(a)
Range #3.14 3.15–4.09 4.10–4.97 $4.98
N events 40 42 44 65
Rate per 1000 patient-years 4.3 4.4 4.7 7.0 0.01
Adjusted relative riska 1.0 0.96 (0.6,1.5) 0.83 (0.5,1.3) 1.10 (0.7,1.7) 0.70
Apolipoprotein A mg/dL
Range #111 112–130 131–151 $152
N events 62 45 47 37
Rate per 1000 patient-years 6.6 4.8 5.1 4.1 0.03
Adjusted relative riska 1.0 0.73 (0.5,1.1) 0.79 (0.5,1.2) 0.66 (0.4,1.0) 0.08
Apolipoprotein B mg/dL
Range #73 74–89 90–110 $111
N events 46 41 55 49
Rate per 1000 patient-years 4.8 4.5 5.7 5.5 0.33
Adjusted relative riska 1.0 0.87 (0.6,1.3) 1.03 (0.7,1.5) 0.88 (0.6,1.3) 0.73
Adjusted relative risks compare quartile of plasma lipids to the lowest quartile (quartile 1) of lipid level.
aAdjusted for age, race, gender, and baseline systolic blood pressure, diabetes mellitus, antihypertensive medication use and serum creatinine
experience a rise in creatinine compared with those in cal characteristics, log triglycerides remained predictive
of an incident rise in creatinine, while HDL cholesterolthe lowest quartile (P , 0.02 for each).
Levels of plasma triglycerides and HDL cholesterol did not. The risk of a rise in creatinine was 1.45 (95%
CI, 1.0, 2.1, P 5 0.04) times greater for threefold higherwere inversely associated with each other (correlation
of 20.5). To discern whether the effects of these lipids (1.09 loge units) triglycerides; HDL cholesterol was not
associated with loss of renal function after adjustmentwere independent, a Poisson regression model with
plasma triglycerides and HDL cholesterol as well as clini- for triglycerides (RR 5 0.72 for an 40 mg/dL increase
in HDL cholesterol; 95% CI, 0.5, 1.1, P 5 0.15). Becausecal and demographic variables was fit. To enhance the
power of the analysis, lipids were modeled as continuous of the high correlation between HDL and HDL-2 choles-
terol (r 5 0.81), HDL-2 was not included in this model.variables with triglycerides log transformed because of
their skewed distribution. In a model containing HDL Using HDL-2 cholesterol rather than HDL cholesterol
yielded similar results.cholesterol, log triglycerides, and demographic and clini-
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Fig. 1. Adjusted relative risk of an incident
rise in creatinine between ARIC visit 1 and
visit 2 for a threefold higher baseline plasma
triglyceride level (1.10 loge units) overall and
in selected subgroups. Relative risks were ad-
justed for sex, race, and baseline age, diabetes
mellitus status, systolic blood pressure, type
of hypertension medication use, and creati-
nine in a Poisson regression model.
To determine the consistency of the relationship be- in addition to the a priori chosen clinical and demo-
graphic characteristics only slightly attenuated the asso-tween increased triglyceride levels and a rise in creati-
nine, analyses were conducted stratified by race, creati- ciations between triglycerides and HDL and a rise in
creatinine (model 3 compared with model 2; Table 3).nine level, diabetes mellitus, and hypertension status at
baseline (Fig. 1). For each threefold higher triglycerides, Further adjustment for insulin levels in nondiabetics sub-
stantially attenuated the associations between HDL cho-the adjusted relative risk of a rise in creatinine was 2.39
(P 5 0.001) among African Americans and 1.31 (P 5 lesterol, triglycerides, and a rise in creatinine (model 4;
Table 3). Among nondiabetics, adjustment for insulin0.20) among whites, a difference in effect of triglycerides
that was not statistically significant (P interaction 5 negated the associations between both triglycerides and
HDL cholesterol and a rise in creatinine (both P . 0.20).0.08). The adjusted relative risk among persons with
normal creatinine at baseline was 1.68 (P 5 0.005). Next, the data were analyzed using change in creati-
nine clearance as the outcome, defined as a $25% de-Among persons with borderline or definite hypercreati-
nemia, the relative risk was 1.35 (P 5 0.35). This disparity crease in creatinine clearance. There were 407 incident
cases during follow-up. Over 93% of cases defined by awas consistent with random variation (P interaction 5
0.78). The adjusted relative risk of a rise in creatinine rise in creatinine met this alternate outcome definition,
but only 48% of persons having a $25% decrease inamong nondiabetics at baseline was 1.48 (P 5 0.04) for
each threefold higher triglycerides and 2.44 (P 5 0.007) calculated creatinine clearance had a creatinine increase
$0.4 mg/dL. After adjusting for age, sex, race, diabetes,among diabetics (P interaction 5 0.19). Additionally, for
each threefold higher triglycerides, the adjusted relative systolic blood pressure, type of antihypertensive medica-
tion, and baseline creatinine clearance, the relative riskrisk of a rise in creatinine was 1.65 (P 5 0.05) and 1.57
(P 5 0.03) for normotensives and hypertensives, respec- of developing a $25% decrease in creatinine clearance
was 1.54 (95% CI 1.2, 1.9, P 5 0.001) for each threefoldtively. Body mass index was not associated with declining
renal function, and further adjustment for it yielded no higher triglycerides. Redefining the outcome as a larger
decline ($30%, $40%) in creatinine clearance resultedmeaningful changes in the association between lipids and
renal dysfunction. in progressively larger relative risks. For each threefold
higher triglycerides, the relative risks of developing aAdjustment for serum glucose as a continuous variable
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Table 3. Relative risks and 95% confidence intervals for a rise in creatinine for threefold higher plasma triglycerides and 30 mg/dL
higher HDL cholesterol
Overall No Diabetes Mellitus Diabetes Mellitus
Lipid Model RR (95% CI) P value RR (95% CI) P value RR (95% CI) P value
Plasma 1. Crude 1.77 (1.3,2.4) 0.0001 1.44 (1.0,2.0) 0.04 1.77 (1.0,3.2) 0.05
triglycerides 2. Adjusteda 1.64 (1.2,2.2) 0.002 1.48 (1.0,2.1) 0.04 2.44 (1.3,4.7) 0.007
3. Glucoseb 1.49 (1.1,2.1) 0.02 1.42 (1.0,2.1) 0.07 1.88 (1.0,3.7) 0.07
4. Fullc 1.37 (1.0,1.9) 0.07 1.25 (0.8,1.9) 0.28 — —
HDL 1. Crude 0.53 (0.4,0.8) 0.0008 0.66 (0.4,1.0) 0.03 0.38 (0.1,1.1) 0.06
cholesterol 2. Adjusteda 0.58 (0.4,0.9) 0.01 0.62 (0.4,1.0) 0.03 0.31 (0.1,1.0) 0.05
3. Glucoseb 0.63 (0.4,0.9) 0.03 0.65 (0.4,1.0) 0.05 0.39 (0.1,1.2) 0.11
4. Fullc 0.70 (0.5,1.1) 0.10 0.75 (0.5,1.2) 0.22 — —
aAdjusted for sex, race, and baseline age, antihypertensive medications, serum creatinine, and systolic blood pressure
bAdjusts for baseline glucose in addition to the factors in model 2
cAdjusts for baseline glucose, insulin in nondiabetics, and the factors in model 2
large decline in creatinine clearance ($30%, $40%) for other lipid levels, demographic, and clinical charac-
were 1.68 (P 5 0.004) and 4.67 (P 5 0.001), both of teristics, higher triglycerides at baseline were associated
which were statistically significant. Adjustment for fast- with a significantly higher risk of creatinine rise during
ing insulin and glucose had only a minimal effect on the follow-up. When insulin levels among nondiabetics were
magnitude of these associations, and triglycerides, but considered in the analysis, however, the effect of triglyc-
not HDL cholesterol, were a statistically significant pre- erides was reduced and no longer significant. In contrast,
dictor of a decline in creatinine clearance. After adjust- when a 25% or greater decline in creatinine clearance
ment for insulin, glucose, and the other covariates, a was used as the outcome, higher plasma triglycerides
threefold higher amount of triglycerides was associated predicted a loss of renal function independent of insulin
with a relative risk of 1.51 (95% CI, 1.2 to 2.0; P 5 0.003) levels. These results raise the possibility that the insulin-
for a 25% decline in creatinine clearance. resistance syndrome may underlie or mediate the ob-
As mentioned previously, ARIC participants on lipid- served associations between lipids and a loss of renal
lowering medications were excluded from these analyses. function. Although BMI is frequently associated with
When the 563 participants on lipid-lowering medications both renal disease and the insulin-resistance syndrome,
were included, the results remained virtually identical in further adjustment for BMI yielded no changes in the
both magnitude and significance. Re-analyzing the data association between lipids and renal dysfunction.
excluding persons who were placed on lipid-lowering Possible mechanisms whereby dyslipidemia causes re-
medications during follow-up (N 5 605, 22 cases of renal nal injury have been reviewed [8, 37, 38]. While the
dysfunction) did not substantially change the results of pathophysiology by which hypercholesterolemia may
any of our analyses. cause damage to the kidney is uncertain, experimental
data support the hypothesis that glomerulosclerosis and
atherosclerosis share common mechanisms [38]. Similar-DISCUSSION
ities in anatomical origin and functional properties ofThis study is the first to our knowledge to assess pro-
glomerular mesangial cells to those of vascular smoothspectively the association between a large number of
muscle cells provide clues to analogous cellular re-lipids and the subsequent decline in renal function in
sponses common to both atherosclerosis and glomerulo-the general population. In this study, HDL, HDL-2 cho-
sclerosis [37, 38]. Many of the studies reviewed havelesterol, and triglycerides were all significant predictors
shown that glomerular lipid deposits and the appearanceof a rise in serum creatinine, a measure of renal function.
of foam cells accompany renal injury in models of hyper-These associations persisted after adjustment for demo-
lipidemia. Experimental data also suggest that dyslipide-graphic and clinical information, including sex, race, age,
mia influences renal injury. In several animal models,systolic blood pressure, diabetes mellitus status, and type
feeding high cholesterol diets were associated with theof antihypertensive medication use. Among the lipids
initiation of renal dysfunction [38], and pharmacologicwe investigated, triglycerides had the strongest and most
lowering of lipids with either clofibrate or lovastatin re-statistically significant association with a future decline
sulted in a reduction of renal injury [39–41].in renal function. After adjustment for clinical and demo-
Several prospective studies in humans have shown angraphic factors, the highest quartile of log triglycerides
association between dyslipidemia and renal disease pro-imparted a 65% higher risk of developing a rise in creati-
gression among patients with proven renal diseasenine $0.4 mg/dL within three years compared with the
lowest quartile of triglycerides. Even after adjustment [18–21]. In the Modification of Diet in Renal Disease
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(MDRD) study, low HDL cholesterol independently the length of follow-up is sufficiently long. In the pilot
predicted the rate of renal decline among 840 partici- phase of the MDRD study [45], this correlation was 0.70
pants, but triglycerides were not examined [20]. In for 15 months of follow-up. The correlation in this study
smaller studies, total cholesterol [21, 22] and LDL choles- with three years of follow-up is likely to be even greater.
terol [22], or apo(B) [22, 23] predicted renal disease Third, our results remained very similar when several
progression. A detailed lipoprotein analysis in 44 pa- different definitions of substantial renal functional de-
tients [18] showed a strong correlation of the rate of cline were applied. While examination of proteinuria
glomerular filtration rate decline with the plasma concen- would have been helpful as an additional confirmation
tration of triglyceride-rich apoB containing lipoproteins of renal dysfunction, urine was not collected in the ARIC
but no significant association with cholesterol-rich apoB- study.
containing lipoproteins. Only one prospective study has We use the term early renal disease progression to
examined dyslipidemia and the risk of renal function reflect the fact that the majority of the individuals are
decline among persons without known renal disease. In making the transition from a “normal” serum creatinine
a subset of 2700 males from the Helsinki Heart Study to an “abnormal” serum creatinine. Although the results
(HHS), a randomized clinical trial originally designed to of this study hold for patients with a normal serum creati-
investigate the ability of gemfibrozil to prevent coronary nine at baseline, we cannot determine that these patients
heart disease, low HDL predicted a rise in creatinine, had no renal pathology at baseline. Thus, we cannot
while no association was seen with triglycerides [10]. conclude that lipids affect renal disease initiation rather
The association between HDL cholesterol and a rise in than early progression.
creatinine was present in both the gemfibrozil treatment A possible concern with our analysis is the phenome-
and placebo groups of the HHS, while no association non of regression to the mean. Because of variability
between triglyceride levels and a rise in creatinine was or measurement error, participants with a low serum
present in either group. The difference between our creatinine measurement at baseline may have a higher
study and the HHS in the relative importance of HDL measurement at follow-up because their baseline mea-
and triglycerides may be due to restriction of the Helsinki surement was lower than their long-term average (or
study to persons with elevated non-HDL cholesterol. In “true”) value [46]. These participants’ serum creatinine
addition, the analysis in the HHS focused on the mean may have merely regressed back to its long-term mean
progression rate in all individuals, not the development level. We identified 32 ARIC participants whose creati-
of hypercreatinemia as in our study. The mean progres- nine was 0.2 mg/dL or greater below the mean at baseline
sion rate was not related to age, a well-demonstrated and whose creatinine measurement at the follow-up visit
risk factor for loss of renal function, and surprisingly was
was 0.4 mg/dL higher. Removing these 32 cases and
more strongly related to HDL cholesterol than blood
repeating our analyses yielded nearly identical results.pressure. Results from the present study provide addi-
Alternatively, defining cases as individuals who had ational evidence that an excess of triglyceride-rich lipo-
normal serum creatinine at baseline and a rise in creati-proteins and associated low HDL cholesterol plays a
nine of $0.4 mg/dL to at least 0.2 mg/dL greater thanlarger role in the decline of renal function than total
the upper limit of normal yielded similar results as well.cholesterol or LDL cholesterol. Our results extend the
Even though the consistent prospective associationHHS findings to a different population with a broader
between lipids and a rise in creatinine was statisticallyrange of lipid measurements.
significant and independent of other risk factors, theAlthough serum creatinine is quite commonly used as
potential for reverse causality is of concern. Lipoproteina measure of renal function, it has been criticized for
abnormalities are very common in end-stage renal dis-being unreliable [42, 43]. Some people with low serum
ease patients [47–49]. The most common abnormalitiescreatinine may suffer from renal dysfunction, while some
are elevated triglycerides and low HDL cholesterol. Inpeople with high serum creatinine do not always have
this analysis of ARIC data, lipids were measured onlyrenal impairment [44]. Nevertheless, we feel it appro-
three years prior to the follow-up determination of creat-priate to use the change in serum creatinine between
inine at visit 2. Dyslipidemia may have been presentbaseline and follow-up as a measure of renal impairment
because of subclinical renal disease at baseline. It is possi-for three reasons. First, most large prospective cohort
ble that like hypertension, dyslipidemia accelerates renalstudies investigating the risk of renal disease progression
disease progression and renal disease increases dyslipi-use serum creatinine as a measure of renal function
demia. An appropriate approach to reduce the effect of[9, 10] since direct measurement of the glomerular filtra-
subclinical disease is to perform a study with longer fol-tion rate is substantially more expensive and time con-
low-up. Serum creatinine measurements will soon besuming. Second, there is a strong correlation between
available from the nine-year follow-up of the ARIC co-declines in the glomerular filtration rate assessed using
125I-iothalamate and changes in serum creatinine when hort. These data will provide an excellent opportunity
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clinical trials have shown that the use of lipid-lowering nine: Results from the “CLUE” study and ARIC study. JAMA
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